The chronic pancreatitis (CP) Type Cambridge 2 as a cause of unclear upper abdominal pain: a radiologically underestimated diagnosis

Abstract

Objective

The time interval from symptom onset to the diagnosis of chronic pancreatitis (CP) remains disproportionately long today due to nonspecific symptoms and the absence of a definitive laboratory marker. Nevertheless, mortality is increased by 3.6 times compared to the general population. Additionally, the risk of developing pancreatic carcinoma is 16 times higher in the presence of CP. According to the current S3 guideline, the morphological staging of CP should be based on the Cambridge Classification for CT/MRCP. Most radiologists morphologically associate CP with Cambridge Stage 4, which is characterized by classic calcifications. The subtle morphologies of earlier Cambridge Stages are often unrecognized, leading to delayed diagnosis. The aim of this study was to diagnose CP at Cambridge Stage 2 as the cause of unexplained upper abdominal discomfort.

Materials and Methods

A retrospective analysis was conducted on 266 patients with unexplained upper abdominal pain who underwent outpatient MRI with MRCP between January 1, 2021, and October 1, 2023. The criteria for Cambridge Stage 2 were evaluated: pancreatic duct in the corpus measuring between 2 and 4 mm, pancreatic hypertrophy, cystic changes < 10 mm, irregularities in the duct, or > 3 pathological side branches. Patients with known tumors or other leading diagnoses, which explained the discomfort, were excluded.

Results

25 patients (15 female, 10 male) met the criteria for CP Stage 2 (9%). Ductal dilation between 2 and 4 mm was visible in 21 cases. Pancreatic hypertrophy was observed in six cases. Cystic changes < 10 mm were identified in three cases. Irregularities in the duct (“wavy duct”) were diagnosed in 19 patients. Dilation of > 3 side branches was recognized in 17 cases. Lipase levels were additionally determined, with 13 patients showing pathologically elevated levels (> 60 U/l).

Conclusions

CP at Cambridge Stage 2 is an important and underestimated diagnosis in patients with unexplained upper abdominal pain in the outpatient setting. Radiologists should pay attention not only to common signs like calcifications, large cysts, or duct strictures but also to subtle changes such as duct irregularities (“wavy duct configuration”) and pathologically dilated side branches, which could lead to a significantly earlier diagnosis of CP. Lipase determination may be an additional indication of chronic pancreatitis in this context.

Key Points

• Early-stage Cambridge 2 CP is an important and underestimated diagnosis in patients with unexplained upper abdominal pain in the outpatient setting.

• Radiologists should pay attention to subtle signs of early CP.

• Additional information about lipase levels can be helpful in the diagnostic process.

Keywords

pancreas - pancreatitis - Cambridge - MR-imaging

Publication History

Received: 28 December 2023

Accepted after revision: 22 February 2024

Article published online:
16 April 2024

• Literatur

• 1 Cohen SM, Kent TS. Etiology, Diagnosis, and Modern Management of Chronic Pancreatitis: A Systematic Review. JAMA Surg 2023; 158: 652-661
• 2 Hart PA, Conwell DL. Chronic Pancreatitis: Managing a Difficult Disease. American Journal of Gastroenterology 2020; 115: 49-55
• 3 Singh VK, Yadav D, Garg PK. Diagnosis and Management of Chronic Pancreatitis: A Review. JAMA – Journal of the American Medical Association 2019; 322: 2422-2434
• 4 Schreyer AG, Jung M, Riemann JF. et al. S3 guideline for chronic pancreatitis – diagnosis, classification and therapy for the radiologist. Fortschr Röntgenstr 2014; 186: 1002-1008
• 5 Schreyer AG, Seidensticker M, Mayerle J. et al. German Terminology of the Revised Atlanta Classification of Acute Pancreatitis: Glossary Based on the New German S3 Guideline on Acute, Chronic, and Autoimmune Pancreatitis. Fortschr Röntgenstr 2021; 193: 909-918
• 6 Löhr JM, Dominguez-Munoz E, Rosendahl J. et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J 2017; 5: 153-199
• 7 Dominguez-Munoz JE, Drewes AM, Lindkvist B. et al. Corrigendum to „Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis“ [Pancreatology 18(8) (2018) 847–854]. Pancreatology 2020; 20: 148
• 8 Dominguez-Munoz JE, Drewes AM, Lindkvist B. et al. Recommendations from the United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis. Pancreatology 2018; 18: 847-854
• 9 Swensson J, Akisik F, Collins D. et al. Is Cambridge scoring in chronic pancreatitis the same using ERCP and MRCP?: A need for revision of standards. Abdom Radiol (NY) 2021; 46: 647-654
• 10 Mayerle J, Hoffmeister A, Witt H. et al. Chronic Pancreatitis. Dtsch Arztebl Int 2013;
• 11 Tirkes T, Shah ZK, Takahashi N. et al. Reporting Standards for Chronic Pancreatitis by Using CT, MRI, and MR Cholangiopancreatography: The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Radiology 2019; 290: 207-215
• 12 Vege SS, Chari ST. Chronic Pancreatitis. N Engl J Med 2022; 386: 869-878
• 13 Beyer G, Hoffmeister A, Lorenz P. et al. Clinical Practice Guideline – Acute and Chronic Pancreatitis. Dtsch Arztebl Int 2022; 119: 495-501
• 14 Grenacher L, Seidensticker M, Schreyer AG. et al. Guideline-based diagnosis of pancreatitis. Radiologe 2021; 61: 548-554
• 15 Hoß KF, Attenberger UI. Classification of pancreatitis. Radiologe 2021; 61: 524-531
• 16 Kim B, Lee SS, Sung YS. et al. Intravoxel incoherent motion diffusion-weighted imaging of the pancreas: Characterization of benign and malignant pancreatic pathologies. Journal of Magnetic Resonance Imaging 2017; 45: 260-269
• 17 Ha J, Choi SH, Kim KW. et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Digestive and Liver Disease 2022; 54: 849-856
• 18 Jia H, Li J, Huang W. et al. Multimodel magnetic resonance imaging of mass-forming autoimmune pancreatitis: differential diagnosis with pancreatic ductal adenocarcinoma. BMC Med Imaging 2021; 21
• 19 Schima W, Böhm G, Rösch CS. et al. Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation. Cancer Imaging 2020; 20
• 20 Pezzilli R, D’Eril GM, Barassi A. Can Serum Pancreatic Amylase and Lipase Levels Be Used as Diagnostic Markers to Distinguish Between Patients With Mucinous Cystic Lesions of the Pancreas, Chronic Pancreatitis, and Pancreatic Ductal Adenocarcinoma?. Pancreas 2016; 45: 1272-1275
• 21 Oh HC, Kwon CIl, El Hajj II. et al. Low Serum Pancreatic Amylase and Lipase Values Are Simple and Useful Predictors to Diagnose Chronic Pancreatitis. Gut Liver 2017; 11: 878-883
• 22 Jalal M, Campbell JA, Hopper AD. Practical guide to the management of chronic pancreatitis. Frontline Gastroenterol 2019; 10: 253-260